ClinicalTrials.gg
CompletedNCT03336177CODEGY65Updated Aug 8, 2018

Understanding Low Gynecological Cancer Delay and Help-seeking Behavior in Older Patients.

An observational study in Gynecologic Cancer, Symptoms and Signs and Aged, sponsored by Institut de Cancérologie de Lorraine. Completed at 1 site in France. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2018-08-08.

Sponsored by Institut de Cancérologie de Lorraine · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
12
Ages
65 Years and older
Sex
Female
01

Study summary

Systematic screening for cervical cancer stops in France at 65 years old. The incidence of certain types of gynecological neoplasia increases with age (endometrium, vulva). Diagnosis delay of 8 months has been described for uterine cancer and longer delays for vulvar cancer.

The aim of our study is to understand help-seeking behavior and its delay for this type of cancer among patients older than 65.

Read the detailed description

Our study assess the reasons for which the patient took time to go to the doctor despite of their symptoms. We use a qualitative methodology. Our study categorizes lived experiences, recorded in semistructured interview transcripts. We use psychodynamic and semiopragmatic analyses of the discourse to obtain hypotheses about possible reasons of the delay in the help-seeking process."

02

Conditions studied

  • Gynecologic Cancer
  • Symptoms and Signs
  • Aged

Keywords

  • gynecology
  • cancer
  • aged
  • delay
  • help-seeking behavior
  • qualitative research
  • semiopragmatic analysis
  • psychodynamic analysis
03

In context

Signs and Symptoms

221 studies on the registry are indexed under Signs and Symptoms; 22 are open to participants now.

This study's enrollment of 12 is below the median of 189 across 58 observational studies indexed under Signs and Symptoms.

Browse Signs and Symptoms studies →

Lead sponsor

Institut de Cancérologie de Lorraine is the lead sponsor of 62 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women of 65 years or more treated or followed at Lorraine Institute of Oncology Diagnosed after 65 years or later of a low gynecological cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women of 65 years or more treated or followed at Lorraine Institute of Oncology
  • Diagnosed after 65 years or later of a low gynecological cancer
  • Without diagnosis of dementia
  • Retained ability to express by herself without assistance
  • Affiliated to public health system
  • Informed and having expressed her non-opposition

Exclusion criteria

Exclusion Criteria:

  • Women under 65 or diagnosed before being 65 of a low gynecological cancer
  • Diagnosed of dementia
  • No longer to express herself
  • Patient deprived of freedom
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
12 participants (actual)
Patient registry
No

Interventions

  • OtherSemi-structured face to face interviews.

    Patients will be interviewed by open-ended questions face to face concerning their past experiences. The recorded interview will be transcribed and analyzed by psychodynamic and semio-pragmatic approach.

06

What researchers measure

Primary outcomes

  1. Experience of help-seeking period for low gynecological cancers.

    Qualitative interview performed at one occasion where the patient describes the experience of the help seeking period she has passed through.

    Time frame: 1 day

Secondary outcomes

  1. Motivators and barriers to help-seeking for low gynecological cancers.

    qualitative methodology using verbal data analysis of semi-structured interview.

    Time frame: 1 day

07

Study locations

1 site
  • Institut de Cancérologie de Lorraine (ICL)
    Vandœuvre-lès-Nancy, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Mar 2018, 4 months.

Of 20 observational studies under Signs and Symptoms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2017
First posted
Nov 8, 2017
StartActual
Oct 30, 2017
Primary completionActual
Mar 12, 2018
CompletionActual
Jul 27, 2018
Last update
Aug 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03336177
Lead sponsor
Institut de Cancérologie de Lorraine
Responsible party
Sponsor
First posted
Nov 8, 2017
Start date
Oct 30, 2017
Primary completion
Mar 12, 2018
Completion
Jul 27, 2018
Last update
Aug 8, 2018

Study contacts

MARCHAL FREDERIC, MD
principal investigator · Institut de Cancérologie de Lorraine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion